Esperion Therapeutics (ESPR) director Hoffman received 79,873 shares
Insider transactions reported
Robert E. Hoffman (director at Esperion Therapeutics Inc., ESPR) reported that they received 79,873 shares on May 28, 2026. After these transactions the filing shows 85,153 shares held directly.
- Reporting person
- Hoffman Robert E.
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| May 28, 2026 | Grant or award (A) | Common Stock1 | +79,873 | - | - | 85,153 direct |
Holdings before and after
- Common Stock: 5,280 to 85,153 direct
Footnotes from the filing
- 1. The awards vest in full on the earlier of (i) May 28, 2027 and (ii) the Issuer's next annual meeting of stockholders following May 28, 2026.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Hoffman report in this ESPR Form 4?
Robert E. Hoffman (director at Esperion Therapeutics Inc., ESPR) reported that they received 79,873 shares on May 28, 2026. After these transactions the filing shows 85,153 shares held directly.
How many ESPR shares does Hoffman hold after this filing?
The filing shows 85,153 shares held directly after the reported transactions. Form 4 reports only the positions it lists, so this may not be every holding.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for ESPR
Across the 27 sessions after earlier ESPR headlines, the stock closed higher 14 times and lower 12 times, with a median move of 3.4% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ESPR | SPY |
|---|---|---|---|
| May 26, 2026 | Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026 | -0.3% | +0.7% |
| May 15, 2026 | Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | +0.0% | -1.2% |
| May 13, 2026 | Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026 | -0.3% | +0.6% |
| May 1, 2026 | Esperion Therapeutics downgraded by H.C. Wainwrightand 1 other headline that session | +55.5% | +0.3% |
| Apr 23, 2026 | Esperion to Report First Quarter 2026 Financial Results on May 7 | -3.0% | -0.4% |
| Apr 6, 2026 | Athyrium Capital Management and Esperion Enter Into $50 Million Japan Royalty Financing to Support Strategic Acquisition of Corstasis Therapeuticsand 1 other headline that session | -2.3% | +0.5% |
Earlier insider filings at ESPR
- Jun 1, 2026Director Fischer Seth H. Z. was granted 79,873 shares, increasing direct ownership by 131% to 141,023 units (SEC Form 4)
- Jun 1, 2026Director Carroll J Martin was granted 79,873 shares, increasing direct ownership by 82% to 177,523 units (SEC Form 4)
- Mar 18, 2026SEC Form 4 filed by Koenig Sheldon L.
- Mar 18, 2026SEC Form 4 filed by Looker Benjamin
- Mar 18, 2026SEC Form 4 filed by Halladay Benjamin
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2013
Follow ESPR and get a push notification the moment its next story breaks.